The Effect of Adding Exenatide to a Thiazolidinedione in Suboptimally Controlled Type 2 Diabetes

2007429 citationsJournal Article

Authors

Bernard Zinman · Eli Lilly (United States)

Byron J. Hoogwerf · Amplyx Pharmaceuticals (United States)

Santiago Durán García · Amplyx Pharmaceuticals (United States)

Denái R. Milton · Cleveland Clinic

Joseph M. Giaconia · Amplyx Pharmaceuticals (United States)

Dennis Dong Hwan Kim · Eli Lilly (United States)

Michael Trautmann

Abstract

Exenatide therapy improved glycemic control, reduced body weight, and caused gastrointestinal symptoms more than placebo in patients with type 2 diabetes that was suboptimally controlled with TZD therapy. ClinicalTrials.gov registration number: NCT00099320. For more information on exenatide click here.

Topics & Keywords

Diabetes Treatment and Management Metabolism, Diabetes, and Cancer Diabetes Management and Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Annals of Internal Medicine

Volume 146, Issue 7, pp. 477-485

DOI: 10.7326/0003-4819-146-7-200704030-00003

Field-Weighted Citation Impact: 38.06